Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul;47(7):1120-1133.
doi: 10.1111/1440-1681.13290. Epub 2020 Mar 20.

The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure

Martin Caprnda  1 , Anthony Zulli  2 , Haaris A Shiwani  3 , Peter Kubatka  4   5 , Slavomira Filipova  6 , Vanda Valentova  5   7 , Katarina Gazdikova  8   9 , Ioana Mozos  10   11 , Andrius Berukstis  12 , Aleksandras Laucevicius  12 , Ivan Rihacek  13 , Jozef Dragasek  14 , Robert Prosecky  15 , Emmanuel E Egom  16   17 , Robert Staffa  18 , Peter Kruzliak  15   18 , Vladimir Krasnik  19
Affiliations
Review

The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure

Martin Caprnda et al. Clin Exp Pharmacol Physiol. 2020 Jul.

Abstract

B-type natriuretic peptide (BNP) exhibits roles in natriuresis and diuresis, making it an ideal drug that may aid in diuresing a fluid-overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these have demonstrated beneficial outcomes. The current challenge for BNP research in acute HF lies in addressing a failure of concept and a reluctance to abandon an ineffective research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP, as well as better integration of basic and clinical science.

Keywords: B-type natriuretic peptide; clinical effectiveness; heart failure; pharmacotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Wong PCY, Guo J, Zhang A. The renal and cardiovascular effects of natriuretic peptides. Adv Physiol Educ. 2017;41:179-185.
    1. Clerico A, Giannoni A, Vittorini S, Passino C. Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones. Am J Physiol Heart Circ Physiol. 2011;301:H12-20.
    1. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003;334:233-239.
    1. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316-322.
    1. Iwanaga Y, Nishi I, Furuich S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure. J Am Coll Cardiol. 2006;47:742-748.

Publication types

Substances